Information  X 
Enter a valid email address

Company Name matching 'ADC Therapeutics SA'

Date
Time Source
Company
Announcement
06 Sep 2019 10:38 pm GNW     ADC Therapeutics SA ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
26 Aug 2019 2:00 pm GNW     ADC Therapeutics SA ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
06 Aug 2019 2:00 pm GNW     ADC Therapeutics SA; SOPHiA GE ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
09 Jul 2019 11:00 am GNW     ADC Therapeutics SA ADC Therapeutics Announces Final Close of Series E Financing Expansion
21 Jun 2019 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
12 Jun 2019 11:00 am GNW     ADC Therapeutics SA ADC Therapeutics Announces Completion of a Series E Financing Expansion
  10:55 am GNW     ADC Therapeutics SA ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma
24 Apr 2019 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics and Adagene Announce License Agreement
20 Feb 2019 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
13 Feb 2019 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
16 Jan 2019 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
03 Jan 2019 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors
05 Dec 2018 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
27 Nov 2018 6:00 am GNW     ADC Therapeutics SA ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
14 Nov 2018 12:30 pm GNW     ADC Therapeutics SA ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting
08 Nov 2018 12:30 pm GNW     ADC Therapeutics SA ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
07 Aug 2018 6:30 am GNW     ADC Therapeutics SA ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t